The main office of represented VC is situated in the Seoul. The company was established in Asia in South Korea.
Among the most popular fund investment industries, there are Pharmaceutical, Cosmetics. Among the most popular portfolio startups of the fund, we may highlight ExoCoBio. For fund there is a match between the country of its foundation and the country of its the most frequent investments - South Korea. Besides, a startup needs to be aged 1 and less years to get the investment from the fund.
The high activity for fund was in 2018. The fund is generally included in less than 2 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The standard case for the fund is to invest in rounds with 6 partakers. Despite the K2 Investment Partners, startups are often financed by SBI Investment, ID Ventures, Dt&Investment. The meaningful sponsors for the fund in investment in the same round are TS Investment, Seven Tree Equity Partners, Quantum Venture Partners.
Related Funds
Fund Name | Location |
3S Landing Pad | California, San Francisco, United States |
Academy Centennial Fund | Durham, North Carolina, United States |
Azure | Redmond, United States, Washington |
Base Case Capital | California, San Francisco, United States |
Bright Success Capital | China, Hong Kong, Hong Kong Island |
Caxton Advantage Life Sciences Fund | New York, New York, United States |
DT&I | - |
Five Seasons Ventures | France, Ile-de-France, Paris |
Halloran Philanthropies | Dayton, Ohio, United States |
InnoSpring Seed Fund | California, Palo Alto, United States |
Lauder Partners | Atherton, California, United States |
LongeVC | Lugano, Switzerland, Ticino |
OPENSAUCE | Ishikawa Prefecture, Japan, Kanazawa |
Orchid Asia Group Management | China, Hong Kong, Hong Kong Island |
ProMutual Group Inc | - |
Spring Tide | Texas, Texas City, United States |
The Vinetta Project | California, Los Angeles, United States |
The Westly Group | California, Menlo Park, United States |
Travel Capitalist Ventures (USA, S Africa, Mideast, India) | California, Irvine, United States |
Yarrow Capital | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
AIGEN Sciences | 16 Oct 2024 | Seoul, Seoul-t'ukpyolsi, South Korea | |||
Poen | $33M | 09 Jul 2024 | Kyonggi-do, Gyeonggi-do, South Korea | ||
ADRO | $4M | 19 Jun 2024 | Kyonggi-do, Gyeonggi-do, South Korea | ||
GenEdit | $24M | 23 Jan 2024 | Berkeley, California, United States | ||
Sky Labs | $18M | 22 Sep 2023 | Seongnam-si, Gyeonggi-do, South Korea | ||
Everon | $43M | 13 Jul 2023 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Lablup | $9M | 20 Apr 2023 | South Korea, Gyeonggi-do, South Korea | ||
Logpresso | $4M | 06 Apr 2023 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Onconic Therapeutics | $22M | 09 Dec 2022 | Seoul, Seoul-t'ukpyolsi, South Korea |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
AIGEN Sciences | 16 Oct 2024 | Seoul, Seoul-t'ukpyolsi, South Korea | |||
Poen | $33M | 09 Jul 2024 | Kyonggi-do, Gyeonggi-do, South Korea | ||
ADRO | $4M | 19 Jun 2024 | Kyonggi-do, Gyeonggi-do, South Korea | ||
GenEdit | $24M | 23 Jan 2024 | Berkeley, California, United States | ||
Sky Labs | $18M | 22 Sep 2023 | Seongnam-si, Gyeonggi-do, South Korea | ||
Everon | $43M | 13 Jul 2023 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Lablup | $9M | 20 Apr 2023 | South Korea, Gyeonggi-do, South Korea | ||
Logpresso | $4M | 06 Apr 2023 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
Onconic Therapeutics | $22M | 09 Dec 2022 | Seoul, Seoul-t'ukpyolsi, South Korea |